Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes
NCT ID: NCT00704275
Last Updated: 2008-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2007-06-30
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
NCT00349440
Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
NCT02121847
Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease
NCT02004067
Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers
NCT00335114
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
NCT00717418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Participants are moderate to severe dry eye patients aged more than 18 years of age
2. Oxford staining scores of more than five.
3. OSDI scores of more than 0.1
Outcome measurements:
Main parameter is staining score (corneal + conjunctival) Other parameter is OSDI score, symptom of ocular surface discomfort score, number of daily artificial tear needed, TBUT, Schirmer I score, cytokines level \& markers Safety parameters: VA, IOP, cyclosporin level
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
0.05% cyclosporin
0.05% cyclosporin eye drop
bid dosage for 4 months
B
Refresh
0.05% cyclosporin eye drop
bid dosage for 4 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.05% cyclosporin eye drop
bid dosage for 4 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OPD Chulalongkorn University Hospital
Bangkok, , Thailand
OPD Chulalongkorn University Hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Vilavun Puangsricharern, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
391/48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.